NCT05687071View on ClinicalTrials.gov

A Long-term Trial of ETC-1002 in Patients With Hyper-LDL Cholesterolemia

PHASE3CompletedINTERVENTIONAL
Enrollment

130

Participants

Timeline

Start Date

February 27, 2023

Primary Completion Date

October 5, 2024

Study Completion Date

November 2, 2024

Conditions
Hyper-low-density Lipoprotein (LDL) Cholesterolemia
Interventions
DRUG

180mg of ETC-1002(bempedoic acid)

180mg, tablet, once daily, for 52 weeks

Trial Locations (1)

Unknown

Rinku General Medical Center, Izumisano

Sponsors
All Listed Sponsors
lead

Otsuka Pharmaceutical Co., Ltd.

INDUSTRY

NCT05687071 - A Long-term Trial of ETC-1002 in Patients With Hyper-LDL Cholesterolemia | Biotech Hunter | Biotech Hunter